semaglutide cvd 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events – REGENHEALTHSOLUTIONS (RHS) Adults with obesity, preexisting CVD

Tracking your progress beyond just the numbers on the scale offers a more complete picture of your health improvements while using GLP-1 medications

Cross-Sectional Associations of Total Plasma Homocysteine with Cortical beta-Amyloid Independently and as a Function of Omega 3 Polyunsaturated Fatty Acid Status in Older Adults at Risk of Dementia

Interim pharmacokinetic and safety updates continue to support the Phase 2 profile, and researchers are closely watching for the larger, longer-duration data that will ultimately shape the regulatory trajectory for the molecule

Figure 3 Metabolic effects Bodyweight reduction GLP-1 has a documented dose-dependent effect on satiety, through central mechanisms in the hypothalamus and brainstem